Objectives To investigate efficacy and safety of thrombolysis and anticoagulation with low dose of urokinase (UK) and low molecular weight heparin (LWMH) in rheumatic mitral stenosis (MS) patients with left atrial thrombus and percutaneous balloon mitral valvuloplasty (PBMV).
Methods Combination UK was given one time a day in the dose of 20 million U for 5–7 days as well as 4100 U low molecularweight heparin calcium two once a day in rheumatic heart disease patients with thrombosis of the left atrial appendage before surgery. Drugs were suspended 2–3 days before PBMV. haemorrhage, embolism and heart function were observed during and after operation.
Results There were 106 cases with atrial fibrillation and 28 cases with left atrial appendage in 173 patients with PBMV. No serious complications were found during and after operation, such as haemorrhage and embolism. Heart function was significantly improved and 14 patients with atrial fibrillation returned to sinus rhythm after operation.
Conclusions Our data suggest that it is effictive and safe of thrombolysis and anticoagulation treatment with low dose of UK and LWMH in rheumatic mitral stenosis patients with left atrial thrombus before PBMV.